We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.75B
AUM Growth
-$879M
Cap. Flow
-$770M
Cap. Flow %
-44.05%
Top 10 Hldgs %
36.57%
Holding
112
New
6
Increased
25
Reduced
47
Closed
16

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$12.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$12M
3
EVH icon
Evolent Health
EVH
+$6.42M
4
MRUS
Merus
MRUS
+$3.85M
5
ACHC icon
Acadia Healthcare
ACHC
+$3.72M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$63M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$55.9M
3
FRPT icon
Freshpet
FRPT
+$48.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$41.7M
5
UNH icon
UnitedHealth
UNH
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Consumer Staples 0%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
26
iRhythm Holdings
IRTC
$4.1B
$26.6M 1.52%
254,300
-143,200
-36% -$15.2M
EVH icon
27
Evolent Health
EVH
$444M
$25.5M 1.46%
2,695,700
+635,700
+31% +$6.42M
SRRK icon
28
Scholar Rock
SRRK
$6.32B
$24.5M 1.4%
761,541
+44,759
+6% +$1.72M
KYMR icon
29
Kymera Therapeutics
KYMR
$9.03B
$21.7M 1.24%
794,437
-239,700
-23% -$8.74M
EXAS
30
DELISTED
Exact Sciences
EXAS
$20.8M 1.19%
480,000
+30,000
+7% +$1.52M
ACHC icon
31
Acadia Healthcare
ACHC
$2.96B
$20.7M 1.18%
681,100
+97,600
+17% +$3.72M
GPCR icon
32
Structure Therapeutics
GPCR
$3.82B
$19.6M 1.12%
1,132,979
+52,016
+5% +$1.27M
SMMT icon
33
Summit Therapeutics
SMMT
$11.9B
$19.2M 1.1%
995,000
-59,000
-6% -$1.18M
EW icon
34
Edwards Lifesciences
EW
$53B
$18.5M 1.06%
255,000
-290,000
-53% -$20.8M
TARS icon
35
Tarsus Pharmaceuticals
TARS
$2.97B
$18.2M 1.04%
354,376
+243,487
+220% +$12M
THC icon
36
Tenet Healthcare
THC
$20.9B
$17.5M 1%
130,000
+800
+0.6% +$105K
LEGN icon
37
Legend Biotech
LEGN
$4B
$17.4M 1%
512,932
+800
+0.2% +$28.7K
IMVT icon
38
Immunovant
IMVT
$8.24B
$16.7M 0.95%
975,803
+66,700
+7% +$1.4M
AZTA icon
39
Azenta
AZTA
$1.54B
$16.5M 0.94%
475,000
– –
INSP icon
40
Inspire Medical Systems
INSP
$1.73B
$15.8M 0.9%
99,250
-30,750
-24% -$5.56M
FOLD
41
DELISTED
Amicus Therapeutics
FOLD
$15.6M 0.89%
1,909,362
-690,063
-27% -$6.39M
WRBY icon
42
Warby Parker
WRBY
$3.26B
$15.2M 0.87%
835,000
-85,000
-9% -$2.03M
MREO
43
Mereo BioPharma
MREO
$43.5M
$15M 0.86%
6,684,247
-2,914,923
-30% -$8.25M
CLDX icon
44
Celldex Therapeutics
CLDX
$3.37B
$14.7M 0.84%
812,653
-409,529
-34% -$9.15M
OSCR icon
45
Oscar Health
OSCR
$8.54B
$13.8M 0.79%
1,050,000
– –
WST icon
46
West Pharmaceutical
WST
$24.8B
$13.5M 0.77%
60,250
-108,500
-64% -$29.9M
VERA icon
47
Vera Therapeutics
VERA
$2.27B
$12.5M 0.72%
520,796
+32,933
+7% +$1.06M
DHR icon
48
Danaher
DHR
$147B
$12.1M 0.69%
+58,800
New +$12.8M
NAMS icon
49
NewAmsterdam Pharma
NAMS
$3.34B
$11M 0.63%
536,111
-231,411
-30% -$5.14M
SRPT icon
50
Sarepta Therapeutics
SRPT
$1.81B
$10.2M 0.58%
159,300
-148,200
-48% -$15.6M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rock Springs Capital Management held 112 positions worth $1.75B, down 33% from $2.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $770M in Q1 2025, closing 16 positions and reducing 47 holdings. Its most notable exit was Freshpet, an estimated $48.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Danaher worth $12.1M.

  • Rock Springs Capital Management's largest Q1 2025 buy was Danaher: 58,800 shares worth $12.1M.
  • Rock Springs Capital Management added most to Tarsus Pharmaceuticals in Q1 2025, an estimated $12M increase.
  • Rock Springs Capital Management's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $63M.
  • Rock Springs Capital Management fully exited Freshpet in Q1 2025, selling an estimated $48.5M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $1.75B portfolio in Q1 2025.
  • Rock Springs Capital Management opened 6 new positions and closed 16 in Q1 2025.
  • Rock Springs Capital Management's portfolio value fell 33% quarter-over-quarter to $1.75B.

Based on Rock Springs Capital Management's 13F filing for Q1 2025, filed 15 May 2025.